“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
Executive Summary
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests
You may also be interested in...
BIO, PhRMA Medicare Payment Rule Comments Seek “Interim” Increase
Industry trade associations are proposing that Medicare reimburse non-pass-through drugs at no less than 88% of AWP in 2004 while CMS reworks its payment setting methodology
BIO, PhRMA Medicare Payment Rule Comments Seek “Interim” Increase
Industry trade associations are proposing that Medicare reimburse non-pass-through drugs at no less than 88% of AWP in 2004 while CMS reworks its payment setting methodology
Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
Managed care organizations may start using functional equivalence as a tool in determining coverage levels, biotech companies agreed during a panel presentation at the Kellogg Biotech Conference in Chicago April 5